运用高效液相色谱法(HPLC)联用示差折光检测器(RID)建立了黄体酮注射液中羟丙基-β-环糊精的含量测定方法。色谱柱为分子排阻色谱柱(Advance Bio SEC 130?,7.8 mm×300 mm,2.7μm),流动相为乙腈-水(20∶80),检测器为示差折光检测器(...运用高效液相色谱法(HPLC)联用示差折光检测器(RID)建立了黄体酮注射液中羟丙基-β-环糊精的含量测定方法。色谱柱为分子排阻色谱柱(Advance Bio SEC 130?,7.8 mm×300 mm,2.7μm),流动相为乙腈-水(20∶80),检测器为示差折光检测器(RID),温度为40℃,柱温为35℃,进样量为20μL,流动相的流速为0.8 m L·min^(-1)。结果表明羟丙基-β-环糊精在0.286~0.858 mg·m L^(-1)范围内线性关系良好(r=0.9999),羟丙基-β-环糊精的平均回收率为100.4%,RSD为0.4%(n=9)。通过重复性试验、加标回收试验、精密度试验、稳定性试验、耐用性试验和样品含量测定表明,所建立的方法操作简洁、准确可靠,可用于黄体酮注射液的质量控制。展开更多
Non-alcoholic fatty liver disease(NAFLD)has become a globally rising issue that can cause liver-related morbidity and mortality.Recent studies have revealed that a high-fat diet(HFD)highly contributes to the prevalenc...Non-alcoholic fatty liver disease(NAFLD)has become a globally rising issue that can cause liver-related morbidity and mortality.Recent studies have revealed that a high-fat diet(HFD)highly contributes to the prevalence and progression of NAFLD via impacting gut microbiota and lipid metabolism signal pathways.Resveratrol(RSV),a natural bioactive compound,has exhibited potential for preventing and alleviating NAFLD.However,due to the poor bioavailability of RSV,its strengths and underlying mechanisms for NAFLD therapeutic potential are poorly understood.To address this,we utilized Hydroxypropyl-beta-Cyclodextrin(HBC)to encapsulate RSV to enhance its water solubility and conducted prevention and intervention experiments in HFD-fed mice.The results showed that the HBC has significantly enhanced the water solubility of RSV by 250-fold and the HBC-RSV better prevented and alleviated the liver steatosis,obesity and abnormal lipid metabolism induced by HFD than RSV alone.Meanwhile,combining HFD and HBC-RSV or RSV prevented HFD mice progressing to NAFLD.Besides,further investigation indicated that RSV could resist liver injury and obesity by modulating gut microbiota,raising the levels of short-chain fatty acids(SCFAs)and activating AMP-activated protein kinase(AMPK)signaling pathway.The activated pathway down-regulated sterol receptor element binding protein 1c(SREBP1c)and acetyl-coenzyme A carboxylase(ACC)to decrease lipid synthesis and up-regulated peroxisome proliferators-activated receptorα(PPARα)to promote the fatty acid oxidation,thus preventing NAFLD.Our findings suggested that water solubility-enhanced RSV beneficially modulated gut microbiota,altered gut microbiota-derived SCFAs,and activated lipid metabolism regulatory pathways,providing potential for NAFLD prevention and alleviation.展开更多
目的:探讨一种新型的含羟丙基-β-环糊精(hydroxypropyl-beta-cyclodextrin,HP-β-CD)的双氯酚酸制剂黏膜下注射对于下颌第三磨牙拔除术后急性疼痛的疗效及其安全性。方法:将100例行第三磨牙拔除术的患者随机分为5组,A^D组为实验组,给...目的:探讨一种新型的含羟丙基-β-环糊精(hydroxypropyl-beta-cyclodextrin,HP-β-CD)的双氯酚酸制剂黏膜下注射对于下颌第三磨牙拔除术后急性疼痛的疗效及其安全性。方法:将100例行第三磨牙拔除术的患者随机分为5组,A^D组为实验组,给予不同剂量术前黏膜下双氯酚酸制剂注射(A组5 mg/mL、B组12.5 mg/mL、C组25 mg/mL、D组50 mg/mL);E组为对照组,给予术前黏膜下生理盐水注射(1 mL)。5组患者均进行标准流程的第三磨牙拔除术,观察5组患者术后6 h VAS评分曲线下面积(area under curve,AUC),以及疼痛发生时间、要求镇痛治疗时间,并记录5组患者药物不良事件及并发症发生情况。结果:与对照组相比,实验组(A^D组)术后6 h VAS评分AUC显著小于对照组(P<0.001),疼痛发生时间、要求镇痛治疗时间均高于对照组(P<0.001)。实验组组内比较,A组、D组VAS评分AUC显著低于B组、C组(P<0.001),而疼痛发生时间、要求镇痛治疗时无显著差异(P=0.459,0.233)。实验组(A^D组)与对照组比较,药物不良事件发生率、术后并发症发生率无显著差异(P=0.839),无特殊处理均自行缓解。结论:羟丙基-β-环糊精包含的双氯酚酸制剂黏膜下注射能够有效改善第三磨牙拔除术后疼痛,无明显不良反应;应用时可首先给予低剂量注射,效果不佳时逐渐大剂量注射。展开更多
文摘运用高效液相色谱法(HPLC)联用示差折光检测器(RID)建立了黄体酮注射液中羟丙基-β-环糊精的含量测定方法。色谱柱为分子排阻色谱柱(Advance Bio SEC 130?,7.8 mm×300 mm,2.7μm),流动相为乙腈-水(20∶80),检测器为示差折光检测器(RID),温度为40℃,柱温为35℃,进样量为20μL,流动相的流速为0.8 m L·min^(-1)。结果表明羟丙基-β-环糊精在0.286~0.858 mg·m L^(-1)范围内线性关系良好(r=0.9999),羟丙基-β-环糊精的平均回收率为100.4%,RSD为0.4%(n=9)。通过重复性试验、加标回收试验、精密度试验、稳定性试验、耐用性试验和样品含量测定表明,所建立的方法操作简洁、准确可靠,可用于黄体酮注射液的质量控制。
基金the National Natural Science Foundation of China(81971837)Natural Science Foundation of Fujian Province,China(2020J05109)Joint Funds for the Innovation of Science and Technology,Fujian Province(2021Y9155).
文摘Non-alcoholic fatty liver disease(NAFLD)has become a globally rising issue that can cause liver-related morbidity and mortality.Recent studies have revealed that a high-fat diet(HFD)highly contributes to the prevalence and progression of NAFLD via impacting gut microbiota and lipid metabolism signal pathways.Resveratrol(RSV),a natural bioactive compound,has exhibited potential for preventing and alleviating NAFLD.However,due to the poor bioavailability of RSV,its strengths and underlying mechanisms for NAFLD therapeutic potential are poorly understood.To address this,we utilized Hydroxypropyl-beta-Cyclodextrin(HBC)to encapsulate RSV to enhance its water solubility and conducted prevention and intervention experiments in HFD-fed mice.The results showed that the HBC has significantly enhanced the water solubility of RSV by 250-fold and the HBC-RSV better prevented and alleviated the liver steatosis,obesity and abnormal lipid metabolism induced by HFD than RSV alone.Meanwhile,combining HFD and HBC-RSV or RSV prevented HFD mice progressing to NAFLD.Besides,further investigation indicated that RSV could resist liver injury and obesity by modulating gut microbiota,raising the levels of short-chain fatty acids(SCFAs)and activating AMP-activated protein kinase(AMPK)signaling pathway.The activated pathway down-regulated sterol receptor element binding protein 1c(SREBP1c)and acetyl-coenzyme A carboxylase(ACC)to decrease lipid synthesis and up-regulated peroxisome proliferators-activated receptorα(PPARα)to promote the fatty acid oxidation,thus preventing NAFLD.Our findings suggested that water solubility-enhanced RSV beneficially modulated gut microbiota,altered gut microbiota-derived SCFAs,and activated lipid metabolism regulatory pathways,providing potential for NAFLD prevention and alleviation.
文摘目的:探讨一种新型的含羟丙基-β-环糊精(hydroxypropyl-beta-cyclodextrin,HP-β-CD)的双氯酚酸制剂黏膜下注射对于下颌第三磨牙拔除术后急性疼痛的疗效及其安全性。方法:将100例行第三磨牙拔除术的患者随机分为5组,A^D组为实验组,给予不同剂量术前黏膜下双氯酚酸制剂注射(A组5 mg/mL、B组12.5 mg/mL、C组25 mg/mL、D组50 mg/mL);E组为对照组,给予术前黏膜下生理盐水注射(1 mL)。5组患者均进行标准流程的第三磨牙拔除术,观察5组患者术后6 h VAS评分曲线下面积(area under curve,AUC),以及疼痛发生时间、要求镇痛治疗时间,并记录5组患者药物不良事件及并发症发生情况。结果:与对照组相比,实验组(A^D组)术后6 h VAS评分AUC显著小于对照组(P<0.001),疼痛发生时间、要求镇痛治疗时间均高于对照组(P<0.001)。实验组组内比较,A组、D组VAS评分AUC显著低于B组、C组(P<0.001),而疼痛发生时间、要求镇痛治疗时无显著差异(P=0.459,0.233)。实验组(A^D组)与对照组比较,药物不良事件发生率、术后并发症发生率无显著差异(P=0.839),无特殊处理均自行缓解。结论:羟丙基-β-环糊精包含的双氯酚酸制剂黏膜下注射能够有效改善第三磨牙拔除术后疼痛,无明显不良反应;应用时可首先给予低剂量注射,效果不佳时逐渐大剂量注射。
